Protara (TARA): Market Capitalization-to-Revenue Ratio
Protara Therapeutics' development of drugs for rare oncological diseases is not subject to the influence of GDP or seasonality. The price-to-sales ratio visualizes the current market value, where determines the latest valuation metric. The future of the business relies on regulatory approval and therapy safety. The company's strategy is based on optimizing R&D expenses for the subsequent licensing of innovative cell therapies.
Metric breakdowns and analytics for Protara (TARA)
- share price and expert price forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Protara Therapeutics|TARA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Protara Tx|TARA - Company Aggregate Debts|Debts to Book Capitalization Protara|TARA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Protara Therapeutics|Intermediate Liquidity Ratio protaratx.com
- earnings and multiples data:
TARA - Net Profit|Expected Net Income Protara Therapeutics|TARA - P/E Multiple|Projected Price to Earnings Ratio Protara Therapeutics Inc|TARA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Protara|TARA - Operating profit EBITDA|Net earnings per share (EPS TTM) Protara Therapeutics|TARA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months protaratx.com|TARA - Earnings growth in current year|Expected net earnings per share growth next year Protara Therapeutics
- sales revenue and business income indicators:
General company analysis:TARA protaratx.com
By developing unique treatments for rare pathologies and oncology, Protara Therapeutics (TARA) is establishing a high-tech scientific hub where business value often outpaces current sales. The P/S multiple compares market capitalization to annual revenue, allowing GURU.Markets investors to determine, through P/S fluctuations, the extent of the premium paid for future revenue growth rates relative to the current asset valuation.
Who Protara Therapeutics competes with
ONC: Price-to-Sales Ratio|Price-to-Revenue Ratio Halozyme HALO|Market Capitalization-to-Revenue Ratio RVMD|AAPG - Price-to-Revenue Ratio|Price to Sales CG Oncology Therapeutics|URGN (UroGen Pharma Ltd.) - Market Cap to Revenue|BCAX: Market Cap to Sales Volume|PSNL (Personalis) - P/S Multiple|P/S Multiple Erasca Inc|Price-to-Revenue Ratio Delcath (DCTH)|YMAB (Y-mAbs Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple AURA (Aura Biosciences, Inc.)|P/S Multiple Candel Therapeutics Inc. CADL|ARAY: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|CTOR: Market Cap to Sales Volume|HURA (TuHURA Biosciences Inc.) - P/S Multiple|FATE: Market Capitalization-to-Revenue Ratio|P/S Multiple WHWK|TCRX - Price to Sales|Price-to-Revenue Ratio Champions Oncology, Inc. CSBR|Market Capitalization-to-Revenue Ratio XBIT|CEL-SCI Corp - P/S Multiple|OSTX - P/S Multiple|Radiopharm Theranostics (RADX) - Price-to-Revenue Ratio|Price-to-Sales Ratio ARTV (Artiva Biotherapeutics)|ANL (Adlai Nortye Ltd) - P/S Multiple|Price to Sales Veru Corporation VERU|Market Cap to Revenue TPST (Tempest Therapeutics)|P/S Multiple xiliotx.com (XLO)|Renovaro - Market Cap to Revenue|Market Cap to Sales Volume MURA (Mural Oncology PLC)|Kairos Pharma Inc - P/S Multiple|Price-to-Revenue Coefficient OnKure Therapeutics Inc OKUR|GDTC: P/S Multiple|Market Cap to Revenue Curis|Price-to-Revenue Ratio Apollomics Inc.|Tharimmune Inc (THAR) - Price-to-Revenue Coefficient|Market Cap to Revenue ADVB (Advanced Biomed Inc)|Market Cap to Sales Volume GNPX|P/S Multiple CLDI (Calidi Biotherapeutics, Inc.)|P/S Multiple sunshinebiopharma.com SBFM|XBIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SLRX (Salarius Pharmaceuticals Inc)|PPBT: P/S Multiple|American Oncology Network, Inc. (AONC) - P/S Multiple|BGNE (BeiGene, Ltd.) - P/S Multiple|Market Cap to Revenue checkpointtx.com (CKPT)|P/S Multiple ELEV|P/S Multiple icadmed.com (ICAD)|Price-to-Revenue Ratio Ikena Oncology IKNA|NTBL: Market Cap to Revenue Ratio|Viracta - P/S Multiple|morphosys.com (MOR) - Market Cap to Revenue|NAYA: P/S Multiple|Price to Sales Ascentage Pharma Group International (AAPGV)
